Results 131 to 140 of about 177,348 (250)

Treatment‐Related Adverse Events and Health‐Related Quality of Life Associated With Immune Checkpoint Inhibitor Treatment for Mucosal Head and Neck Squamous Cell Carcinoma: A Scoping Review

open access: yesHead &Neck, EarlyView.
ABSTRACT Background Supportive care needs of patients receiving immune checkpoint inhibitors (ICIs) for head and neck squamous cell carcinoma (HNSCC) are ill‐defined. Hence, known treatment‐related adverse events (TRAEs) and health‐related quality of life (HRQoL) associated with ICI treatment for HNSCC were examined to inform future supportive care ...
N. D. O'Donnell   +11 more
wiley   +1 more source

Botulinum Toxin for First Bite Syndrome: A Symptom‐Guided “Follow‐The‐Pain” Injection Strategy

open access: yesHead &Neck, EarlyView.
ABSTRACT Background To evaluate botulinum toxin type A (BoNT‐A) for First Bite Syndrome (FBS) and assess a symptom‐guided “Follow‐the‐Pain” (FTP) injection strategy in patients with incomplete response to standard treatment. Methods Consecutive patients with postoperative FBS were treated with ultrasound‐guided intraparotid BoNT‐A injection.
Rosario Marchese‐Ragona   +5 more
wiley   +1 more source

Edible Bird's Nest Attenuates Neuroinflammation and Cognitive Impairment in a Model of Chronic Fatigue Syndrome. [PDF]

open access: yesFood Sci Nutr
Wang X   +10 more
europepmc   +1 more source

Indirect Comparison of Neoadjuvant Treatment Strategies for Muscle‐Invasive Bladder Cancer: ddMVAC and Perioperative Durvalumab‐Gemcitabine‐Cisplatin Versus Gemcitabine‐Cisplatin: A Systematic Review and Network Meta‐Analysis of Randomised Controlled Trials

open access: yesInternational Journal of Cancer, EarlyView.
Optimizing neoadjuvant therapy for muscle‐invasive bladder cancer patients who are eligible for cisplatin remains difficult, owing particularly to high toxicity and recurrence rates. This meta‐analysis compared dose‐dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) against durvalumab plus gemcitabine‐cisplatin (D‐GC) and GC alone ...
Maurin Helen Mangold   +12 more
wiley   +1 more source

Elevated serum levels of interleukin-11 and matrix metalloproteinase-9 in myalgic encephalomyelitis/chronic fatigue syndrome. [PDF]

open access: yesFront Immunol
Chinnappan B   +8 more
europepmc   +1 more source

Functional status of women with and without potentially life‐threatening maternal conditions after 6 months postpartum: A cohort study

open access: yesInternational Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective The aim of this study was to evaluate the impact of potentially life‐threatening maternal conditions (PLTCs) on functional disability at 6 months postpartum. Methods This prospective cohort study was done at 10 hospitals in Tigray, northern Ethiopia. A total of 1027 postpartum women (341 with PLTCs and 686 without) were enrolled into
Fitiwi Tinsae Baykemagn   +3 more
wiley   +1 more source

Cognition in menopausal women

open access: yesInternational Journal of Gynecology &Obstetrics, EarlyView.
Abstract Cognitive health in postmenopausal women is significantly affected by hormonal shifts, especially the drop in estrogen levels. This review explores the intricate relationship between menopause and cognitive functions across six domains: perception, attention, memory, language, executive functioning, and motor skills.
Suvarna Khadilkar   +3 more
wiley   +1 more source

Patient‐Reported Outcomes with Selpercatinib Treatment Among Patients with RET‐Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO‐001 Trial

open access: yesThe Oncologist, EarlyView., 2021
Abstract Background Medullary thyroid cancer (MTC) standard of care includes multikinase inhibitors (MKIs), which can exacerbate disease‐related diarrhea, primarily because of non‐RET kinase inhibition. We report diarrhea and other patient‐reported outcomes (PROs) with selpercatinib, a highly selective RET inhibitor, among patients with RET‐mutant MTC ...
Lori J. Wirth   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy